美国波士顿哈佛医学院的研究人员认为,细胞环素D1抑制剂有可能为一些人乳腺肿瘤的治疗提供一种特效方法。Qunyan Yu和Yan Geng以及PiotrSicinski的预测基于他们对经遗传工程化处理的小鼠进行的实验研究,这些受试小鼠的细胞环素D1基因均已被敲除。Sicinski教授认为,研究结果表明细胞环素D1有可能是对过度表达c-erb-B2的人乳腺肿瘤(约占所有类型肿瘤的30％〕治疗性干预的一个良好靶标。 Researchers at Harvard Medical School in Boston, the United States believe that, cytochromes D1 inhibitors may provide some of the effects of treatment for some human breast tumors. The predictions of Qunyan Yu and Yan Geng and PiotrSicinski are based on their experimental study of genetically engineered mice whose genes for the gene encoding the Cyclin D1 have been knocked out. Sicinski believes the findings suggest that Cyclin D1 may be a good target for therapeutic intervention in human breast tumors overexpressing c-erb-B2, which is about 30% of all types of tumors.